Scientific Reports · 2021 · 53 citations · 34 references
Life SciencesMedicinal ChemistryPharmacologyDrug DiscoveryMolecular VirologyVirologyAntiviral PharmacologyComputational Drug DiscoveryEnzyme InhibitionMolecular DockingProtein-ligand DockingProtein-protein DockingAntiviral Drug DesignAntiviral Structure-activity RelationshipsDocking-based Drug DesignDruggable Target DiscoveryMolecular Docking Of InhibitorsSars-cov-2 InfectionViral Protease InhibitionViral Proteases
Abstract Novel SARS-CoV-2, an etiological factor of Coronavirus disease 2019 (COVID-19), poses a great challenge to the public health care system. Among other druggable targets of SARS-Cov-2, the main protease (M pro ) is regarded as a prominent enzyme target for drug developments owing to its crucial role in virus replication and transcription. We pursued a computational investigation to identify M pro inhibitors from a compiled library of natural compounds with proven antiviral activities using a hierarchical workflow of molecular docking, ADMET assessment, dynamic simulations and binding free-energy calculations. Five natural compounds, Withanosides V and VI, Racemosides A and B, and Shatavarin IX, obtained better binding affinity and attained stable interactions with M pro key pocket residues. These intermolecular key interactions were also retained profoundly in the simulation trajectory of 100 ns time scale indicating tight receptor binding. Free energy calculations prioritized Withanosides V and VI as the top candidates that can act as effective SARS-CoV-2 M pro inhibitors.
34
WHO Declares COVID-19 a Pandemic.
Domenico Cucinotta, Maurizio Vanelli · PubMed · 2020 · 7.8K citations · Full text
Public Health, Infectious Disease Control, Infectious Diseases +17
Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors
Zhenming Jin, Xiaoyu Du, Yechun Xu et al. · Nature · 2020 · 4.5K citations · Full text